Twice-Daily Budesonide Inhalation Suspension in Infants and Children <4 and ≥4 Years of Age with Persistent Asthma

Abstract

A retrospective analysis, based on a randomized, placebo-controlled, 12-week study in children 6 months to 8 years of age with persistent asthma, was performed to compare the efficacy and safety of budesonide inhalation suspension 0.25 mg and 0.5 mg twice daily vs. placebo in children <4 and ≥4 years of age. Both age groups demonstrated significant (p ≤ 0.050) improvement in nighttime and daytime asthma symptom scores and decreased bronchodilator use compared with placebo. In addition, the safety profile of twice-daily budesonide inhalation suspension was favorable in both age groups.

• Asthma
• Budesonide inhalation suspension
• Corticosteroids
• Inhaled
• Nebulization
• Pediatric